Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts. - 2Best Quest for new employment Site for You to Track down Amazing open doors
- 3Vote In favor of Your Favored Occasion Arranging Administration
- 4One dead, six wounded in various crime-related shootings in Israel over the weekend
- 5Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Massive supernova explosion may have created a binary black hole
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- Finding the Universe of Workmanship: Individual Encounters in Imagination
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Death toll from floods in Afghanistan rises to 61
- A Russian fighting for Ukraine conned the Kremlin out of $500,000 by faking his own death
